<DOC>
	<DOCNO>NCT00869895</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) E7050 give orally patient advance solid tumor .</brief_summary>
	<brief_title>A Dose-Finding Study E7050 Administered Orally Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Age 18 year . 2 . Histologically and/or cytologically confirm metastatic solid tumor , progress treatment approved therapy , standard effective therapy available . 3 . Adequate bone marrow function . 4 . Adequate renal function . 5 . Adequate liver function . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 7 . Life expectancy &gt; 3 month . 8 . Be willing able comply study protocol , give write informed consent . Additional inclusion criterion additional 15 patient recruit expand MTD cohort : 9 . At least one tumor lesion diameter &gt; = 2 cm measurable accord Modified RECIST . 1 . Any condition may preclude oral intake oral absorption , history gastrointestinal malabsorption , surgery involve gastro and/or intestinal anastomosis within 4 week prior start study drug . 2 . Untreated unstable know primary metastatic central nervous system ( CNS ) tumor ( stability show contrastenhanced computed tomography magnetic resonance imaging scan least 8 week apart , recent scan obtain within 28 day prior start study treatment ) . 3 . Known human immunodeficiency virus ( HIV ) , hepatitis B C , severe/uncontrolled infection intercurrent illness ( unrelated tumor ) . 4 . Prior surgery , radiotherapy , chemotherapy , biologic therapy investigational drug within 4 week prior start study drug . Prior immunotherapy , hormonal , molecular target therapy within 2 week prior start study treatment ( except gonadorelin analogue therapy prostate cancer allow ) . ( All acute toxicity relate prior treatment resolve ) . 5 . Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within 6 month prior start study drug . 6 . Requiring therapeutic anticoagulant therapy ( prophylactic dose heparin low molecular weight heparin allow ) . 7 . Poorly control hypertension ( defined change hypertensive therapy within 3 month start study drug ) hypertension diagnose screening ( defined repeat blood pressure measurement 160/90 mmHg high ) . 8 . Pregnancy lactation . Female patient childbearing potential must negative pregnancy test inclusion study , must agree use medically acceptable method contraception ( e.g . abstinence , doublebarrier method [ e.g . condom + spermicide , condom + diaphragm spermicide ] , IUD , vasectomise partner ) start Screening throughout entire study period 2 month last dose study drug . Those female patient use hormonal contraceptive must also use additional approve method contraception ( describe previously ) start Cycle 1 Day 1 , continue throughout entire study period 2 month last dose study drug . Perimenopausal woman must amenorrheic least 12 month ; otherwise pregnancy test require . Male patient must agree use contraceptive method ( e.g. , abstinence , doublebarrier method [ e.g. , condom + spermicide , condom + partner diaphragm spermicide ] ) . Additional exclusion criterion additional 15 patient recruit expand MTD cohort : 9 . History malignancy present malignancy ( except treat nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>